FoundationAct בדיקת דם לאבחון גנומי | FoundationOne CDx רפואה מותאמת לסרטן
Latest Medical News
Sep 09, 2021| Information meeting on FoundationOne CDx Cancer Genomic Profile
FoundationOne Liquid CDx
FoundationOne Liquid CDx
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer | Nature Communications
FoundationOne Liquid CDx
FoundationOne Liquid
Testing for MET Exon 14 Skipping | TABRECTA® (capmatinib) tablets
FoundationOne Liquid CDx (F1 Liquid CDx) – P190032/S005 | FDA
Foundation Medicine receives FDA approval for pan-tumour biopsy test
Foundation Medicine Heme Brochure for Patients with Blood cancers and Sarcomas
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Business Wire
Multi-gene Testing (NGS) for PIK3CA Mutations
FDA Approves FoundationOne Liquid CDx for Advanced Cancer
FoundationOne Liquid CDx
First Comprehensive Next-gen Sequencing based Pan-Tumor Liquid Biopsy Test Approved - Onco'Zine
Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer - Antonarakis - 2022 - The Prostate - Wiley Online Library
Liquid Biopsy: Clinical Overview
Micromachines | Free Full-Text | The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy
FoundationOne®CDx Technical Information Foundation Medicine, Inc. 150 Second Street, Cambridge, MA 02141 Phone: 617.418.2200 I
JCI Insight - Multiparametric liquid biopsy analysis in metastatic prostate cancer
Multi-gene Testing (NGS) for PIK3CA Mutations
FDA Approves Blood Tests That Can Help Guide Cancer Treatment - NCI
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval | Evaluate
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Technology Networks
